Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Elderly-onset rheumatoid arthritis.

Y Yazici1, S A Paget

  • 1Department of Medicine, Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York, USA.

Rheumatic Diseases Clinics of North America
|September 16, 2000
PubMed
Summary

Age significantly alters disease presentation in elderly-onset rheumatoid arthritis (EORA) compared to younger-onset rheumatoid arthritis (YORA). Understanding these differences is crucial for advancing immune system research and therapeutic strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis.

Osteoarthritis and cartilage·2021
Same author

Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.

Osteoarthritis and cartilage·2019
Same author

A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee.

Osteoarthritis and cartilage·2017
Same author

A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.

Osteoarthritis and cartilage·2017
Same author

Erosions in rheumatoid arthritis: is there less here than meets the eye?

Clinical and experimental rheumatology·2014
Same author

Monotherapy for rheumatoid arthritis treatment?

Clinical and experimental rheumatology·2014

Area of Science:

  • Immunology
  • Rheumatology
  • Gerontology

Background:

  • Age influences the clinical presentation of various autoimmune diseases, including hyperthyroidism and systemic lupus erythematosus.
  • Differences in disease phenotype are observed between elderly-onset rheumatoid arthritis (EORA) and younger-onset rheumatoid arthritis (YORA).

Purpose of the Study:

  • To highlight the impact of aging on the immune system.
  • To explore the medical and therapeutic implications of age-related differences in rheumatoid arthritis.
  • To advance the understanding and treatment of EORA by comparing it with YORA.

Main Methods:

  • Comparative analysis of clinical presentations between EORA and YORA.
  • Review of existing literature on age-related disease modifications.

Related Experiment Videos

  • Exploration of potential therapeutic strategies based on observed differences.

    • Main Results:

    • Distinct disease phenotypes exist between EORA and YORA.
    • These phenotypic differences underscore the significant role of the aging immune system.
    • The observed variations have direct medical and therapeutic relevance.

    Conclusions:

    • Recognizing the differences and similarities between YORA and EORA is essential for optimizing therapeutic choices.
    • Further investigation into these age-related variations can lead to a better definition of rheumatoid arthritis pathogenesis and origin.
    • Improved classification of age-related autoimmune conditions can enhance patient outcomes.